

## Life Sciences Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.

For further information on the points included in this form, see [Reporting Life Sciences Research](#). For further information on Nature Research policies, including our [data availability policy](#), see [Authors & Referees](#) and the [Editorial Policy Checklist](#).

### ► Experimental design

#### 1. Sample size

Describe how sample size was determined.

Sample size was largely determined by the availability of patients and families with this genetic defect.

#### 2. Data exclusions

Describe any data exclusions.

No samples or animals were excluded from the analyses in this manuscript; statement are in materials and methods.

#### 3. Replication

Describe whether the experimental findings were reliably reproduced.

This I confirm.

#### 4. Randomization

Describe how samples/organisms/participants were allocated into experimental groups.

No randomization used; Grouping on the basis of genotype.

#### 5. Blinding

Describe whether the investigators were blinded to group allocation during data collection and/or analysis.

No blinding has been used.

Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.

#### 6. Statistical parameters

For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
- A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- A statement indicating how many times each experiment was replicated
- The statistical test(s) used and whether they are one- or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
- A description of any assumptions or corrections, such as an adjustment for multiple comparisons
- The test results (e.g.  $P$  values) given as exact values whenever possible and with confidence intervals noted
- A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
- Clearly defined error bars

See the web collection on [statistics for biologists](#) for further resources and guidance.

## ► Software

Policy information about [availability of computer code](#)

### 7. Software

Describe the software used to analyze the data in this study.

Excel, GraphPad.

For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). *Nature Methods* [guidance for providing algorithms and software for publication](#) provides further information on this topic.

## ► Materials and reagents

Policy information about [availability of materials](#)

### 8. Materials availability

Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.

KO-animals were provided by KOMP at UC Davis as described in the manuscript.

### 9. Antibodies

Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).

Commercial antibodies were used: Antibody for human SELENBP1 western blotting: Sigma - SAB2108611 affinity purified rabbit polyclonal. Anti-V5 Invitrogen R960 mouse monoclonal. Anti-actin Novus Biologicals AC-15, mouse monoclonal.

### 10. Eukaryotic cell lines

a. State the source of each eukaryotic cell line used.

Well documented HT29 and SW480 colon cancer cell lines have been bought from Sigma.

b. Describe the method of cell line authentication used.

Authentication by Sigma.

c. Report whether the cell lines were tested for mycoplasma contamination.

Before use cell lines were tested in house for mycoplasma and were both negative.

d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by [ICLAC](#), provide a scientific rationale for their use.

HT29 and SW480 colon cancer cell lines have not been listed by ICLAC as contaminated cell lines.

## ► Animals and human research participants

Policy information about [studies involving animals](#); when reporting animal research, follow the [ARRIVE guidelines](#)

### 11. Description of research animals

Provide details on animals and/or animal-derived materials used in the study.

We have added this information to the materials and methods section.

Policy information about [studies involving human research participants](#)

### 12. Description of human research participants

Describe the covariate-relevant population characteristics of the human research participants.

Not applicable; Patients were referred for routine metabolic and genetic testing.